ImmunovantInc Price to Book Value from 2010 to 2024
IMVT Stock | USD 30.40 0.07 0.23% |
Check ImmunovantInc financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImmunovantInc main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 30.1 M or Other Operating Expenses of 251.5 M, as well as many exotic indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.79. ImmunovantInc financial statements analysis is a perfect complement when working with ImmunovantInc Valuation or Volatility modules.
ImmunovantInc | Price to Book Value |
About ImmunovantInc Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include ImmunovantInc income statement, its balance sheet, and the statement of cash flows. ImmunovantInc investors use historical funamental indicators, such as ImmunovantInc's Price to Book Value, to determine how well the company is positioned to perform in the future. Although ImmunovantInc investors may use each financial statement separately, they are all related. The changes in ImmunovantInc's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ImmunovantInc's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ImmunovantInc Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ImmunovantInc. Please read more on our technical analysis and fundamental analysis pages.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of ImmunovantInc Correlation against competitors. For more information on how to buy ImmunovantInc Stock please use our How to Invest in ImmunovantInc guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for ImmunovantInc Stock analysis
When running ImmunovantInc's price analysis, check to measure ImmunovantInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmunovantInc is operating at the current time. Most of ImmunovantInc's value examination focuses on studying past and present price action to predict the probability of ImmunovantInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmunovantInc's price. Additionally, you may evaluate how the addition of ImmunovantInc to your portfolios can decrease your overall portfolio volatility.
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |
Is ImmunovantInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmunovantInc. If investors know ImmunovantInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmunovantInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.81) | Return On Assets (0.27) | Return On Equity (0.45) |
The market value of ImmunovantInc is measured differently than its book value, which is the value of ImmunovantInc that is recorded on the company's balance sheet. Investors also form their own opinion of ImmunovantInc's value that differs from its market value or its book value, called intrinsic value, which is ImmunovantInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmunovantInc's market value can be influenced by many factors that don't directly affect ImmunovantInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmunovantInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmunovantInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmunovantInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.